Kura Oncology (NASDAQ:KURA) Reaches New 1-Year Low - Time to Sell?

Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) reached a new 52-week low during mid-day trading on Tuesday . The company traded as low as $6.34 and last traded at $6.38, with a volume of 434096 shares. The stock had previously closed at $6.60.

Analyst Ratings Changes

KURA has been the subject of a number of research reports. Cantor Fitzgerald upgraded shares of Kura Oncology to a "strong-buy" rating in a research report on Tuesday, March 4th. UBS Group decreased their price target on shares of Kura Oncology from $27.00 to $14.00 and set a "buy" rating on the stock in a research note on Thursday, March 6th. Wedbush restated an "outperform" rating and set a $36.00 price target on shares of Kura Oncology in a research report on Thursday, February 27th. JMP Securities restated a "market outperform" rating and issued a $28.00 target price on shares of Kura Oncology in a report on Thursday, February 6th. Finally, Scotiabank lowered their price objective on Kura Oncology from $18.00 to $10.00 and set a "sector perform" rating for the company in a research report on Wednesday, January 8th. Three equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Kura Oncology presently has a consensus rating of "Moderate Buy" and an average price target of $25.50.

Kura Oncology Stock Performance

The stock has a market capitalization of $475.65 million, a P/E ratio of -2.50 and a beta of 0.83. The stock has a 50 day moving average of $7.68 and a 200 day moving average of $11.51. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47.

Kura Oncology (NASDAQ:KURA - Get Free Report) last released its earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.65) by $0.43. The firm had revenue of $53.88 million for the quarter, compared to analyst estimates of $57.96 million. Equities analysts predict that Kura Oncology, Inc. will post -2.44 EPS for the current year.

Insider Transactions at Kura Oncology

In other news, SVP Thomas James Doyle sold 4,949 shares of the company's stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $38,948.63. Following the sale, the senior vice president now owns 88,193 shares of the company's stock, valued at approximately $694,078.91. This represents a 5.31 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Mollie Leoni sold 4,963 shares of Kura Oncology stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $39,058.81. Following the completion of the transaction, the insider now directly owns 88,253 shares of the company's stock, valued at $694,551.11. This represents a 5.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 11,729 shares of company stock worth $92,307 in the last 90 days. 5.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in shares of Kura Oncology by 14.6% during the 4th quarter. Vanguard Group Inc. now owns 4,818,898 shares of the company's stock valued at $41,973,000 after purchasing an additional 615,211 shares in the last quarter. RA Capital Management L.P. acquired a new position in Kura Oncology during the fourth quarter valued at approximately $38,769,000. Millennium Management LLC increased its holdings in Kura Oncology by 180.1% during the fourth quarter. Millennium Management LLC now owns 2,367,148 shares of the company's stock worth $20,618,000 after buying an additional 1,521,954 shares during the last quarter. Geode Capital Management LLC raised its position in Kura Oncology by 2.4% during the third quarter. Geode Capital Management LLC now owns 1,780,509 shares of the company's stock worth $34,798,000 after acquiring an additional 41,535 shares in the last quarter. Finally, Franklin Resources Inc. grew its position in shares of Kura Oncology by 1.5% in the 3rd quarter. Franklin Resources Inc. now owns 1,588,401 shares of the company's stock valued at $28,687,000 after acquiring an additional 23,113 shares during the period.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.